Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Guidance on the use of antiviral drugs for influenza in acute care facilities in Canada, 2014-2015.

Stiver HG, Evans GA, Aoki FY, Allen UD, Laverdière M.

Can J Infect Dis Med Microbiol. 2015 Jan-Feb;26(1):e5-8.

2.

Guidance for practitioners on the use of antiviral drugs to control influenza outbreaks in long-term care facilities in Canada, 2014-2015 season.

Aoki FY, Allen UD, Stiver HG, Laverdière M, Skowronski D, Evans GA.

Can J Infect Dis Med Microbiol. 2015 Jan-Feb;26(1):e1-4.

3.

Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.

Apter D, Wheeler CM, Paavonen J, Castellsagué X, Garland SM, Skinner SR, Naud P, Salmerón J, Chow SN, Kitchener HC, Teixeira JC, Jaisamrarn U, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Mindel A, de Sutter P, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group.

Clin Vaccine Immunol. 2015 Apr;22(4):361-73. doi: 10.1128/CVI.00591-14. Epub 2015 Feb 4.

4.

Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.

Castellsagué X, Naud P, Chow SN, Wheeler CM, Germar MJ, Lehtinen M, Paavonen J, Jaisamrarn U, Garland SM, Salmerón J, Apter D, Kitchener H, Teixeira JC, Skinner SR, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, de Carvalho NS, Peters K, Tjalma WA, Safaeian M, Raillard A, Descamps D, Struyf F, Dubin G, Rosillon D, Baril L.

J Infect Dis. 2014 Aug 15;210(4):517-34. doi: 10.1093/infdis/jiu139. Epub 2014 Mar 8.

5.

Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study.

Jaisamrarn U, Castellsagué X, Garland SM, Naud P, Palmroth J, Del Rosario-Raymundo MR, Wheeler CM, Salmerón J, Chow SN, Apter D, Teixeira JC, Skinner SR, Hedrick J, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, de Carvalho NS, Germar MJ, Peters K, Paavonen J, Bozonnat MC, Descamps D, Struyf F, Dubin GO, Rosillon D, Baril L; HPV PATRICIA Study Group.

PLoS One. 2013 Nov 19;8(11):e79260. doi: 10.1371/journal.pone.0079260. eCollection 2013. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/cea59317-929c-464a-b3f7-e095248f229a.

6.

The beneficial effects of neuraminidase inhibitor drug therapy on severe patient outcomes during the 2009-2010 influenza A virus subtype H1N1 pandemic.

Aoki FY, Hayden FG.

J Infect Dis. 2013 Feb 15;207(4):547-9. doi: 10.1093/infdis/jis727. Epub 2012 Nov 29. No abstract available.

PMID:
23204176
8.

The use of antiviral drugs for influenza: Guidance for practitioners 2012/2013.

Aoki FY, Allen UD, Stiver HG, Evans GA.

Can J Infect Dis Med Microbiol. 2012 Winter;23(4):e79-92.

9.
10.

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G; HPV PATRICIA Study Group.

Lancet Oncol. 2012 Jan;13(1):89-99. doi: 10.1016/S1470-2045(11)70286-8. Epub 2011 Nov 8. Erratum in: Lancet Oncol. 2012 Jan;13(1):e1.

PMID:
22075171
11.

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmerón J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M; HPV PATRICIA Study Group.

Lancet Oncol. 2012 Jan;13(1):100-10. doi: 10.1016/S1470-2045(11)70287-X. Epub 2011 Nov 8. Erratum in: Lancet Oncol. 2012 Jan;13(1):e1.

PMID:
22075170
12.

Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18.

Szarewski A, Poppe WA, Skinner SR, Wheeler CM, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, Castellsagué X, Teixeira JC, Hedrick J, Jaisamrarn U, Limson G, Garland S, Romanowski B, Aoki FY, Schwarz TF, Bosch FX, Harper DM, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group.

Int J Cancer. 2012 Jul 1;131(1):106-16. doi: 10.1002/ijc.26362. Epub 2011 Oct 23.

13.

Famciclovir: a focus on efficacy and safety.

Mubareka S, Leung V, Aoki FY, Vinh DC.

Expert Opin Drug Saf. 2010 Jul;9(4):643-58. doi: 10.1517/14740338.2010.485189. Review.

PMID:
20429777
14.

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.

Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group.

Lancet. 2009 Jul 25;374(9686):301-14. doi: 10.1016/S0140-6736(09)61248-4. Epub 2009 Jul 6. Erratum in: Lancet. 2010 Sep 25;376(9746):1054.

PMID:
19586656
15.

Influenza virus shedding: excretion patterns and effects of antiviral treatment.

Aoki FY, Boivin G.

J Clin Virol. 2009 Apr;44(4):255-61. doi: 10.1016/j.jcv.2009.01.010. Epub 2009 Mar 9. Review. No abstract available.

PMID:
19272835
16.

Acyclovir bioavailability in patients with acute myelogenous leukemia treated with daunorubicin and cytarabine.

Sitar DS, Aoki FY, Bow EJ.

J Clin Pharmacol. 2008 Aug;48(8):995-8. doi: 10.1177/0091270008319708. Epub 2008 May 21. No abstract available.

PMID:
18495946
17.

Fever and skin redness in a 10-year-old boy.

Fenella ST, Aoki FY.

CMAJ. 2008 May 20;178(11):1427-8. doi: 10.1503/cmaj.071555. No abstract available.

18.

The use of antiviral drugs for influenza: recommended guidelines for practitioners.

Allen UD, Aoki FY, Stiver HG.

Can J Infect Dis Med Microbiol. 2006 Sep;17(5):273-84.

21.

Use of antiviral prophylaxis in influenza outbreaks in long term care facilities.

McGeer A, Sitar DS, Tamblyn SE, Faron K, Orr P, Aoki FY.

Can J Infect Dis. 2000 Jul;11(4):187-92.

22.

Influenza virus susceptibility and resistance to oseltamivir.

Aoki FY, Boivin G, Roberts N.

Antivir Ther. 2007;12(4 Pt B):603-16. Review.

PMID:
17944268
23.

Famciclovir for the management of genital herpes simplex in patients with inadequate response to aciclovir or valaciclovir.

Sacks SL, Aoki FY.

Clin Drug Investig. 2005;25(12):803-9. No abstract available.

PMID:
17532725
24.

Short-course therapy for recurrent genital herpes and herpes labialis.

Spruance S, Aoki FY, Tyring S, Stanberry L, Whitley R, Hamed K.

J Fam Pract. 2007 Jan;56(1):30-6. Review. No abstract available.

PMID:
17217895
25.

Famciclovir for the treatment of recurrent genital herpes: a clinical and pharmacological perspective.

Vinh DC, Aoki FY.

Expert Opin Pharmacother. 2006 Nov;7(16):2271-86. Review.

PMID:
17059383
26.

Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding.

Wald A, Selke S, Warren T, Aoki FY, Sacks S, Diaz-Mitoma F, Corey L.

Sex Transm Dis. 2006 Sep;33(9):529-33.

PMID:
16540883
27.

Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial.

Aoki FY, Tyring S, Diaz-Mitoma F, Gross G, Gao J, Hamed K.

Clin Infect Dis. 2006 Jan 1;42(1):8-13. Epub 2005 Nov 23. Erratum in: Clin Infect Dis. 2006 Feb 15;42(4):588.

PMID:
16323085
28.

Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: a randomized, double-blind, controlled trial.

Sacks SL, Aoki FY, Martel AY, Shafran SD, Lassonde M.

Clin Infect Dis. 2005 Oct 15;41(8):1097-104. Epub 2005 Sep 12.

PMID:
16163627
29.

Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine.

Bernstein DI, Aoki FY, Tyring SK, Stanberry LR, St-Pierre C, Shafran SD, Leroux-Roels G, Van Herck K, Bollaerts A, Dubin G; GlaxoSmithKline Herpes Vaccine Study Group.

Clin Infect Dis. 2005 May 1;40(9):1271-81. Epub 2005 Mar 24.

PMID:
15825029
30.
31.

Early administration of oral oseltamivir increases the benefits of influenza treatment.

Aoki FY, Macleod MD, Paggiaro P, Carewicz O, El Sawy A, Wat C, Griffiths M, Waalberg E, Ward P; IMPACT Study Group.

J Antimicrob Chemother. 2003 Jan;51(1):123-9.

PMID:
12493796
32.

Glycoprotein-D-adjuvant vaccine to prevent genital herpes.

Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, Tyring S, Aoki FY, Slaoui M, Denis M, Vandepapeliere P, Dubin G; GlaxoSmithKline Herpes Vaccine Efficacy Study Group.

N Engl J Med. 2002 Nov 21;347(21):1652-61.

33.
34.

Management of genital herpes in HIV-infected patients.

Aoki FY.

Herpes. 2001 Jul;8(2):41-5. Review.

PMID:
11867017
35.

Oseltamivir: a clinical and pharmacological perspective.

Doucette KE, Aoki FY.

Expert Opin Pharmacother. 2001 Oct;2(10):1671-83. Review.

PMID:
11825310
36.

Dermacase. Herpes simplex virus.

Jassal DS, Ross LR, Aoki FY, Embil JM.

Can Fam Physician. 2001 Dec;47:2475, 2479. No abstract available.

37.
38.

An outbreak of methicillin resistant Staphylococcus aureus on a burn unit: potential role of contaminated hydrotherapy equipment.

Embil JM, McLeod JA, Al-Barrak AM, Thompson GM, Aoki FY, Witwicki EJ, Stranc MF, Kabani AM, Nicoll DR, Nicolle LE.

Burns. 2001 Nov;27(7):681-8.

PMID:
11600247
39.

Vitamin A and risk of HIV-1 seroconversion among Kenyan men with genital ulcers.

MacDonald KS, Malonza I, Chen DK, Nagelkerke NJ, Nasio JM, Ndinya-Achola J, Bwayo JJ, Sitar DS, Aoki FY, Plummer FA.

AIDS. 2001 Mar 30;15(5):635-9.

PMID:
11317002
40.

Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Zanamivir Study Group.

Aoki FY, Fleming DM, Griffin AD, Lacey LA, Edmundson S.

Pharmacoeconomics. 2000 Feb;17(2):187-95.

PMID:
10947341
41.

Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group.

Romanowski B, Aoki FY, Martel AY, Lavender EA, Parsons JE, Saltzman RL.

AIDS. 2000 Jun 16;14(9):1211-7.

PMID:
10894286
42.

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, Rode A, Kinnersley N, Ward P.

Lancet. 2000 May 27;355(9218):1845-50. Erratum in: Lancet 2000 Nov 25;356(9244):1856.

PMID:
10866439
43.

Prospects for control of herpes simplex virus disease through immunization.

Stanberry LR, Cunningham AL, Mindel A, Scott LL, Spruance SL, Aoki FY, Lacey CJ.

Clin Infect Dis. 2000 Mar;30(3):549-66. Review.

PMID:
10722443
44.

Zanamivir. A potent and selective inhibitor of influenza A and B viruses.

Aoki FY, Hayden FG.

Clin Pharmacokinet. 1999;36 Suppl 1:v-ix. Review. No abstract available.

PMID:
10429834
45.

Amantadine acetylation may be effected by acetyltransferases other than NAT1 or NAT2.

Bras AP, Hoff HR, Aoki FY, Sitar DS.

Can J Physiol Pharmacol. 1998 Jul-Aug;76(7-8):701-6.

PMID:
10030449
46.

Respiratory failure in a man with bone and lung lesions.

Embil JM, Aoki FY, Hershfield ES, Meyers MP.

Hosp Pract (1995). 1998 Apr 15;33(4):211-4, 219. No abstract available.

PMID:
9562844
47.

Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group.

Shafran SD, Singer J, Zarowny DP, Deschênes J, Phillips P, Turgeon F, Aoki FY, Toma E, Miller M, Duperval R, Lemieux C, Schlech WF 3rd.

J Infect Dis. 1998 Jan;177(1):252-5.

PMID:
9419201
48.

Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, Bohnen AM, Hirst HM, Keene O, Wightman K.

N Engl J Med. 1997 Sep 25;337(13):874-80.

49.

Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea.

Choudhri SH, Hawken M, Gathua S, Minyiri GO, Watkins W, Sahai J, Sitar DS, Aoki FY, Long R.

Clin Infect Dis. 1997 Jul;25(1):104-11.

PMID:
9243044
50.

Topical undecylenic acid for herpes simplex labialis: a multicenter, placebo-controlled trial.

Shafran SD, Sacks SL, Aoki FY, Tyrrell DL, Schlech WF 3rd, Mendelson J, Rosenthal D, Gill MJ, Bader RL, Chang I.

J Infect Dis. 1997 Jul;176(1):78-83.

PMID:
9207352

Supplemental Content

Support Center